Not Yet RecruitingNot Applicable

Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.

100 participantsStarted 2025-12

Plain-language summary

The goal of this study is to understand the long-term treatment strategies in children and adolescents diagnosed with ERA or JPsA who received secukinumab and achieved inactive disease and to evaluate the long-term treatment effectiveness of secukinumab in the ERA or JPsA patients in the postauthorization setting.

Who can participate

Age range6 Years – 17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * In the BIKER registry, males and females ≥ 6 years old and ≤ 17 years old diagnosed with ERA according to the ILAR-criteria or JPsA according to the ILAR or the Vancouver criteria, who initiated at least one dose of secukinumab after it was approved in Germany and according to the label. * Written informed consent from parent/legal guardian and assent from minor patient (11-17 years of age) for participating in the BIKER registry and for this study enrolment. Exclusion Criteria: * Patients taking other biologic immunomodulating agent(s) or Janus kinase (JAK) inhibitors concomitantly with secukinumab at index date. * Patients participating in any interventional trials at index date.

What they're measuring

Number of patients who had the following long-term treatment strategy after achieving inactive disease on secukinumab

Timeframe: Up to 5 years

Number of patients experiencing at least one episode of flare

Timeframe: Up to 5 years

Trial details

NCT IDNCT07190053

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2029-09-18

Contact for this trial

Novartis Pharmaceuticals

+41613241111 novartis.email@novartis.com